Aquestive Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 2026 total revenue was $7.6 million compared with $12.8 million in Q3 2025, primarily due to quarterly fluctuations in Suboxone product orders.
- For the first 9 months of 2026, total revenue increased 14% to $35.8 million from $31.5 million in the same period in 2025, including $5 million of Zevra-related royalty revenue.
- Q3 2026 research and development expenses were $4.3 million compared with $4.5 million in Q3 2025, while selling, general and administrative expenses were $14.2 million compared with $15.3 million.
- For the first 9 months of 2026, research and development expenses decreased to $12.4 million from $14 million, and selling, general and administrative expenses decreased to $39.2 million from $47 million.
- Q3 2026 net loss was $16.5 million, or $0.13 per basic and diluted share, compared with $15.4 million, or $0.14 per basic and diluted share, in Q3 2025.
- For the first 9 months of 2026, net loss was $47.4 million, or $0.38 per basic and diluted share, including an $11.7 million one-time loss on extinguishment of debt; excluding that item, net loss was $35.7 million.
- Non-GAAP adjusted EBITDA loss was $12.2 million in Q3 2026 compared with $8.6 million in Q3 2025; for the first 9 months of 2026, it narrowed to $19.2 million from $35.5 million.
- Cash and cash equivalents were $90.3 million at September 30th, 2026, excluding the $10 million upfront Libervant license fee received in October.
- Aquestive received a $10 million upfront payment for Libervant and is eligible for up to an additional $47.5 million in contingent regulatory and commercial milestone payments, plus a mid-teens royalty on annual U.S. net sales; it will remain the exclusive manufacturer and supplier under a long-term supply agreement.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Q3 2026 Aquestive Therapeutics Inc. earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Faith Pomeroy-Ward from Aquestive.
Please go ahead. Thank you, operator.
Good morning, and welcome to today's call. On today's call, I am joined by Dan Barber, President and Chief Executive Officer, and Ernie Toth, Chief Financial Officer, who are going to provide an overview of the company's reported financial results for the third quarter ended September 30, 2026, and a business update on recent developments, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Matt Greenhawt, Chief Medical Officer, Melina Cioffi, Senior Vice President, Regulatory Affairs, Sherry Korczynski, Chief Commercial Officer, and Dr. Matthew Davis, Chief Development Officer. As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call and related supplemental materials will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call.
To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of third quarter 2026 results. A description of these measures, along with a reconciliation to GAAP, can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website. During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language as outlined in yesterday's earnings release, as well as the risks and uncertainties affecting the company as described in the Risk Factors section and in other sections included in the company's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 4, 2026, and in its subsequent quarterly reports on Form 10-Q and current reports on Form 8-K.
As with any pharmaceutical company with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development, regulatory approval, and commercialization of its products and other matters related to operations. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements. All forward-looking statements attributable to Aquestive or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday. The company assumes no obligation to update its forward-looking statements or outlook or guidance after the date of this conference call, whether as a result of new information, future events, or otherwise, except as required under applicable law.
Now, I would like to turn the call over to Dan.
Good morning, and thank you for joining us today. This morning, I am pleased to tell you that we continue to execute right on schedule. in March, I told you that we would resubmit our Anaphylm dibutepinephrine sublingual film application before the end of the third quarter, and we did. I also told you that we would out-license Libervant diazepam buccal film rather than launch it ourselves, and we did. I told you that we would refinance our debt before principal payments became due in June, and we did. I told you we expected to have $70 million or more of cash and cash equivalents at year-end, and I'm pleased to tell you that we now expect to end the year with more than $70 million in cash and cash equivalents. In fact, as we sit here today, we are right where we expected to be.
Our lead asset, Anaphylm, is under review with the FDA and has an assigned goal date that is only 132 days away, or if you are an investor, since this is our earnings call, only 88 trading days. We are now focused on the next set of deliverables in our execution story. Our organization is ramping up for the U.S. launch of Anaphylm following FDA approval, and we are now hiring our district sales managers. We expect to file Anaphylm in Canada before the end of the year, and we are on track to file in Europe in the first quarter of next year. Our ex-U.S. licensing activities also continue, and we expect to have more to say in the months to come. Now, let's talk more about Anaphylm in the U.S. Everywhere I go and everyone I talk to in the allergy community can align behind one important concept.
When a person is having a severe allergic reaction, the only thing they care about is making it stop as fast as possible. That's it. That's where we believe Anaphylm will shine if approved by the FDA. Stopping a severe allergic reaction is a function of many things, including having a rescue product with you, using the rescue product without hesitation, and having your symptoms abate quickly. That is why we believe speed is the ultimate differentiator, and we will continue to focus on this as we interact with the allergy community. Our presentations at the upcoming American College of Allergy, Asthma & Immunology in Phoenix this month will highlight these views. This is also why I continue to see the opportunity for Anaphylm as significant. I continue to believe the market will transition from auto-injectors to new and improved technologies like Anaphylm. The market remains large and growing.
We expect the overall U.S. market for epinephrine products, measured by total prescriptions, to once again grow year-over-year in 2027, and we see plenty of opportunity for continued market growth in the years to come. From a development standpoint, we are answering the FDA's information requests as we receive them and will continue to do so. At this time, we have nothing new to report on the review. In terms of timing, while the FDA has assigned a six-month review period, we remain prepared and hopeful for the possibility of an earlier decision. However, we do not control the FDA's timelines or how they prioritize their workload. Therefore, we are keeping our expectations on receiving its decision by March 16th, 2027. In terms of expectations, we recognize that our story in 2027 will be one of execution.
As we look towards a spring launch of Anaphylm, if approved by the FDA, I'd like to outline for you how we will judge success in 2027. In other words, what are the green shoots to look for in 2027? First, we are determined to show ongoing progress with payers via both percentage of covered lives and quality of coverage. We will update you as these happen. We have engaged in the pre-approval information exchange, or PIE, discussions with the top four PBMs in the country, along with many downstream plans, and will continue to advance productive dialogue as much as possible prior to approval. Second, we want to see uptake in the places where we show up. Post-launch, we will provide you with a view of our progress among the physicians our sales reps are calling on. This is a place we must show progress.
Third, we will track the efficiency of our spending. How many dollars are we spending versus the uptake we see? This will be an important measure as we look to scale our launch quarter by quarter. Now let's briefly talk about Libervant. We are excited to have out-licensed Libervant diazepam buccal film to Eton Pharmaceuticals. We have waited a long time for Libervant to be available to patients, and we expect this to finally come to fruition in 2027, if approved. We believe Eton is the right commercial team to launch Libervant, and we look forward to working with them in 2027 and beyond. While Libervant is not central to our growth story, it is an important product for patients and could also be an important cash contributor to the company. Now let's turn to the pipeline.
Long term, our goal is to become the leading provider of cutting-edge medications for patients who need to control their immune responses. We intend to do this through not only becoming a full-fledged commercial organization with deep expertise in allergy, dermatology, and pulmonology, but also through building a new pipeline of development assets. We see 2027 as a pivotal year for our AdrenaVerse pipeline. In 2027, we would like to provide meaningful clinical data on AQST-108 for atopic dermatitis, as well as bring additional AdrenaVerse-driven indications through proof of concept, utilizing our library of epinephrine prodrugs. Now that our development team has resubmitted the Anaphylm application in the U.S., we expect to focus more energy on these efforts. If you look at where we're going, there's a lot to be excited about. We are only a few months away from our FDA goal date for Anaphylm.
We are expanding into ex-U.S. territories. We have managed our cash tightly and remain on track to fund Anaphylm's launch, if approved, and we will have more focus on our pipeline as we move into 2027. With that, I will turn the call over to Ernie.
Thank you, Dan, and good morning, everyone. By now, you will have seen our third quarter 2026 financial results in the earnings release issued last evening and detailed in our Form 10-Q. As we typically do, we will address most of the detailed discussion during our Q&A. I will focus my remarks on our financial performance, operating expenses, and the disciplined capital allocation that supports our next phase of execution. As Dan outlined, we continue to execute against the commitments we made at the beginning of the year. We resubmitted the Anaphylm application before the end of the third quarter. We completed the Libervant licensing transaction. We refinanced our debt in May before scheduled principal payments under the prior notes would have begun. And through disciplined management of our spending and liquidity, we now expect to end 2026 with more than $70 million in cash and cash equivalents.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
